Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Support basic research to uncover biological/genetic causes of cancer health disparities through innovative studies, methodologies, and data analysis.
Funder: National Institutes of Health
Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | Additional cycles through November 2027
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period max 2 years.
Summary: Supports innovative basic research into biological/genetic causes of cancer health disparities, including mechanistic studies, new methodologies, and secondary data analyses.
Key Information: Clinical trials are not allowed; applications must focus on biological mechanisms underlying cancer health disparities and not solely on age or sex differences.
Description
This opportunity from the National Institutes of Health (NIH), led by the National Cancer Institute (NCI), funds exploratory and developmental (R21) research projects focused on the basic biological and genetic mechanisms underlying cancer health disparities. The program aims to support pilot and feasibility studies that investigate the biological contributors to disparities in cancer incidence, progression, and outcomes among different racial, ethnic, and underserved populations. Projects may include mechanistic studies, development and testing of new methodologies or models, and secondary data analyses. The initiative also seeks to build a nationwide cohort of scientists with expertise in cancer health disparities research and to expand resources and tools (e.g., biospecimens, patient-derived models) necessary for this field.
